{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:45:31Z","timestamp":1788482731344,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to (1) describe longitudinal trends in patient-reported oral adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in patients receiving multidisciplinary oral care during outpatient cancer drug therapy, and (2) evaluate concordance between PRO-CTCAE and clinician-reported CTCAE scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Conducted at the Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital (June\u2013December 2023), oral adverse events were assessed using PRO-CTCAE and CTCAE at baseline and every 3\u00a0weeks up to 24\u00a0weeks. Concordance for dry mouth and oral mucositis was evaluated using paired same-day scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients receiving multidisciplinary oral care, 85.2% experienced at least one oral adverse event, most commonly dry mouth. Based on PRO-CTCAE, symptoms rated as moderate or higher were reported in fewer than 10% of cases for most items. Notably, over half of patients reported persistent dry mouth of at least mild severity, and 20\u201330% of other symptoms also remained. These findings suggest that even lower-grade symptoms may persist and affect quality of life. Concordance between PRO-CTCAE and CTCAE was limited, with 31.1% of patients reporting greater dry mouth severity than clinicians documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patient-reported oral adverse events, as assessed by PRO-CTCAE, were frequently mild but persistent throughout outpatient chemotherapy, suggesting a cumulative impact on quality of life. Concordance between PRO-CTCAE and clinician-reported CTCAE was limited, indicating that clinician assessments may underestimate symptoms such as dry mouth. These findings underscore the need to integrate patient-reported outcomes into routine oral care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-025-10126-3","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:15:47Z","timestamp":1763018147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5198-7257","authenticated-orcid":false,"given":"Yuki","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-4840","authenticated-orcid":false,"given":"Kouji","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-224X","authenticated-orcid":false,"given":"Yoshitomi","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5433-4854","authenticated-orcid":false,"given":"Masaaki","family":"Kotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4802-2984","authenticated-orcid":false,"given":"Akira","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"10126_CR1","volume-title":"Japanese Association of Oral Supportive Care in Cancer: Clinical Guidance of Management for Mucositis","author":"Japanese Association of Supportive Care in Cancer","year":"2020","unstructured":"Japanese Association of Supportive Care in Cancer (2020) Japanese Association of Oral Supportive Care in Cancer: Clinical Guidance of Management for Mucositis. Kanehara Co., Tokyo"},{"key":"10126_CR2","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121\u20135127. https:\/\/doi.org\/10.1200\/JCO.2007.12.4784","journal-title":"J Clin Oncol"},{"issue":"34","key":"10126_CR3","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1200\/JCO.2007.13.3330","volume":"25","author":"DW Bruner","year":"2007","unstructured":"Bruner DW (2007) Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? J Clin Oncol 25(34):5345\u20135347. https:\/\/doi.org\/10.1200\/JCO.2007.13.3330","journal-title":"J Clin Oncol"},{"key":"10126_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051\u20131059. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639","journal-title":"JAMA Oncol"},{"key":"10126_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-017-0022-5","author":"T Kawaguchi","year":"2017","unstructured":"Kawaguchi T, Azuma K, Sano M et al (2017) The Japanese version of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. Journal of Patient-Reported Outcomes. https:\/\/doi.org\/10.1186\/s41687-017-0022-5","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"10126_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-017-0012-7","volume":"1","author":"T Miyaji","year":"2017","unstructured":"Miyaji T, Iioka Y, Kuroda Y et al (2017) Japanese translation and linguistic validation of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (Pro-ctcae). J Patient Rep Outcomes 1:8. https:\/\/doi.org\/10.1186\/s41687-017-0012-7","journal-title":"J Patient Rep Outcomes"},{"key":"10126_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/PROM.S256567","volume":"13","author":"LM Minasian","year":"2022","unstructured":"Minasian LM, O\u2019Mara A, Mitchell SA (2022) Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE\u00ae to provide two distinct and complementary perspectives. Patient Relat Outcome Meas 13:249\u2013258. https:\/\/doi.org\/10.2147\/PROM.S256567","journal-title":"Patient Relat Outcome Meas"},{"key":"10126_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040641","author":"Y Sakai","year":"2025","unstructured":"Sakai Y, Katsura K, Kotake M, Toyama A (2025) A cross-sectional survey of oral adverse events and oral management needs in outpatients receiving cancer drug therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17040641","journal-title":"Cancers (Basel)"},{"key":"10126_CR9","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV et al (2020) MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126:4423\u20134431. https:\/\/doi.org\/10.1002\/cncr.33100","journal-title":"Cancer"},{"key":"10126_CR10","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.21.01208","volume":"39","author":"V Mercadante","year":"2021","unstructured":"Mercadante V, Jensen SB, Smith DK et al (2021) Salivary gland hypofunction and\/or xerostomia induced by nonsurgical cancer therapies: ISOO\/MASCC\/ASCO guideline. J Clin Oncol 39:2825\u20132843. https:\/\/doi.org\/10.1200\/JCO.21.01208","journal-title":"J Clin Oncol"},{"key":"10126_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jamaoto.2016.0656","volume":"142","author":"AD Falchook","year":"2016","unstructured":"Falchook AD, Green R, Knowles ME et al (2016) Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg 142:517\u2013523. https:\/\/doi.org\/10.1001\/jamaoto.2016.0656","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10126_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2152\/jmi.71.82","volume":"71","author":"H Arahori","year":"2024","unstructured":"Arahori H, Kondo K, Imai Y et al (2024) Symptomatic adverse events of chemotherapy in breast cancer patients: using CTCAE, PRO-CTCAE, and EORTC QLQ-C30. J Med Invest 71:82\u201391. https:\/\/doi.org\/10.2152\/jmi.71.82","journal-title":"J Med Invest"},{"key":"10126_CR13","unstructured":"NCI. PRO-CTCAE\u00ae ITEMS-JAPANESE Item Library, version 1.0. Accessed 1 Mar 2024"},{"key":"10126_CR14","unstructured":"Correspondence between PRO-CTCAE and CTCAE terminologies. Accessed 1 Mar 2024"},{"key":"10126_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"10126_CR16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jpainsymman.2014.02.009","volume":"48","author":"P Wilberg","year":"2014","unstructured":"Wilberg P, Hjermstad MJ, Ottesen S, Herlofson BB (2014) Chemotherapy-associated oral sequelae in patients with cancers outside the head and neck region. J Pain Symptom Manage 48:1060\u20131069. https:\/\/doi.org\/10.1016\/j.jpainsymman.2014.02.009","journal-title":"J Pain Symptom Manage"},{"key":"10126_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00520-012-1551-3","volume":"21","author":"RM Speck","year":"2013","unstructured":"Speck RM, Demichele A, Farrar JT et al (2013) Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. Support Care Cancer 21:549\u2013555. https:\/\/doi.org\/10.1007\/s00520-012-1551-3","journal-title":"Support Care Cancer"},{"key":"10126_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00520-010-0827-8","volume":"18","author":"SB Jensen","year":"2010","unstructured":"Jensen SB, Pedersen AML, Vissink A et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18:1039\u20131060. https:\/\/doi.org\/10.1007\/s00520-010-0827-8","journal-title":"Support Care Cancer"},{"key":"10126_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI182661","volume":"134","author":"C Paz","year":"2024","unstructured":"Paz C, Glassey A, Frick A et al (2024) Cancer therapy\u2013related salivary dysfunction. J Clin Invest 134:e182661. https:\/\/doi.org\/10.1172\/JCI182661","journal-title":"J Clin Invest"},{"key":"10126_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.oraloncology.2007.01.015","volume":"44","author":"SB Jensen","year":"2008","unstructured":"Jensen SB, Mouridsen HT, Reibel J, Br\u00fcnner N, Nauntofte B (2008) Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol 44:162\u2013173. https:\/\/doi.org\/10.1016\/j.oraloncology.2007.01.015","journal-title":"Oral Oncol"},{"key":"10126_CR21","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s00520-012-1398-7","volume":"20","author":"A Boltong","year":"2012","unstructured":"Boltong A, Keast R, Aranda S (2012) Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer 20:2765\u20132774. https:\/\/doi.org\/10.1007\/s00520-012-1398-7","journal-title":"Support Care Cancer"},{"key":"10126_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103512","author":"A Boltong","year":"2014","unstructured":"Boltong A, Aranda S, Keast R et al (2014) A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0103512","journal-title":"PLoS One"},{"key":"10126_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470","author":"E Basch","year":"2006","unstructured":"Basch E, Iasonos A, Mcdonough TA et al (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. https:\/\/doi.org\/10.1016\/S1470","journal-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study"},{"key":"10126_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100127","volume":"8","author":"S Huynh-Dagher","year":"2025","unstructured":"Huynh-Dagher S, Duong T-A, Tournigand C, Kempf E, Lam\u00e9 G (2025) Concordance between patient-reported outcomes and CTCAE clinician-reported toxicities during outpatient chemotherapy courses: a retrospective cohort study in routine care. ESMO Real World Data Digital Oncology 8:100127. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100127","journal-title":"ESMO Real World Data Digital Oncology"},{"key":"10126_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ et al (2021) Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials 18:104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120","journal-title":"Clin Trials"},{"key":"10126_CR26","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1805052","journal-title":"N Engl J Med"},{"key":"10126_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.eururo.2018.11.033","volume":"75","author":"EM Basch","year":"2019","unstructured":"Basch EM, Scholz M, de Bono JS et al (2019) Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint. Eur Urol 75:929\u2013937. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.033","journal-title":"Eur Urol"},{"key":"10126_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/jog.15811","volume":"50","author":"T Takenaga","year":"2024","unstructured":"Takenaga T, Kuji S, Tanabe KI et al (2024) Prospective analysis of patient-reported outcomes and physician-reported outcomes with gynecologic cancer chemotherapy. J Obstet Gynaecol Res 50:75\u201385. https:\/\/doi.org\/10.1111\/jog.15811","journal-title":"J Obstet Gynaecol Res"},{"key":"10126_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07793-5","volume":"31","author":"S Gu","year":"2023","unstructured":"Gu S, Menzer C, Hay JL et al (2023) PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients. Support Care Cancer 31:337. https:\/\/doi.org\/10.1007\/s00520-023-07793-5","journal-title":"Support Care Cancer"},{"key":"10126_CR30","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1007\/s00520-019-04781-6","volume":"27","author":"AC Tan","year":"2019","unstructured":"Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D (2019) Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. Support Care Cancer 27:4771\u20134777. https:\/\/doi.org\/10.1007\/s00520-019-04781-6","journal-title":"Support Care Cancer"},{"key":"10126_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3332","author":"AC Dueck","year":"2020","unstructured":"Dueck AC, Scher HI, Bennett AV et al (2020) Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3332","journal-title":"JAMA Oncol"},{"key":"10126_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jval.2015.02.018","volume":"18","author":"E Basch","year":"2015","unstructured":"Basch E, Spertus J, Dudley RA et al (2015) Methods for developing patient-reported outcome-based performance measures (PRO-PMs). Value Health 18:493\u2013504. https:\/\/doi.org\/10.1016\/j.jval.2015.02.018","journal-title":"Value Health"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10126-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:31:41Z","timestamp":1765949501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10126-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10126"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10126-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6970435\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Niigata University School of Medicine (approval number: 2023-0315). As this was a retrospective observational study using existing medical records, we employed an opt-out method for obtaining consent in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. Information about the study was publicly disclosed on the Niigata University School of Medicine website, providing participants with the opportunity to refuse participation. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1059"}}